Entries by Russell Radefeld

KindredBio Announces Pricing of Initial Public Offering

SAN FRANCISCO, CA, Dec 11, 2013 (Marketwired via COMTEX) — Kindred Biosciences, Inc. (KindredBio), a biopharmaceutical company focused on saving and improving the lives of pets, today announced the pricing of its initial public offering of 7,500,000 shares of its common stock at an initial public offering price of $7.00 per share for a total […]

KindredBio Announces Launch of Initial Public Offering

SAN FRANCISCO, California. (December 2, 2013) – Kindred Biosciences, Inc. (KindredBio), a biopharmaceutical company focused on saving and improving the lives of pets, announced the commencement of its initial public offering of 5,750,000 shares of its common stock, at an anticipated initial public offering price between $6.00 and $8.00 per share. KindredBio also expects to […]

KindredBio Announces Initiation of Pivotal Clinical Study for CereKin™

CereKin™ (KIND-001), a novel oral cytokine inhibitor, is expected to be a major step forward in the treatment of dogs with arthritis. SAN FRANCISCO, California – Kindred Biosciences, Inc. (KindredBio) announced today that it has initiated a pivotal clinical trial for CereKin™ (KIND-001) in dogs with osteoarthritis. The trial is being conducted under a protocol […]

KindredBio Announces Protocol Concurrences from the FDA on Pivotal Studies

FDA issues the equivalent of a Special Protocol Assessment on KIND-001 and KIND-002 Pivotal Studies. SAN FRANCISCO, California. (July 2, 2013) – Kindred Biosciences, Inc. (KindredBio) announced today that it has received concurrences from the Center for Veterinary Medicine of the U.S. Food and Drug Administration (FDA) on its protocols for two pivotal (Phase III) […]

KindredBio Announces the Filing of an INAD for Laminitis in Horses

KIND-005 is expected to be a major new therapy for the treatment of laminitis in horses. SAN FRANCISCO, California. (March 26, 2013) – Kindred Biosciences, Inc. (KindredBio) announced today the filing of an Investigational New Animal Drug Application (INAD) with the U.S. Food and Drug Administration (FDA) for KIND-005. KIND-005 inhibits a biological pathway that […]

KindredBio Announces Filing of an Investigational New Animal Drug Application for KIND-002

KIND-002 is expected to be a major new therapy for severe cutaneous diseases in dogs​ SAN FRANCISCO, California. (February 3, 2013) – Kindred Biosciences, Inc. (KindredBio) announced today the filing of an Investigational New Animal Drug Application (INAD) with the U.S. Food and Drug Administration (FDA) for KIND-002. KIND-002 is a potent molecule being developed […]

KindredBio Elects Ervin Veszprémi, Former Global Head of Marketing for Novartis Animal Health, to Its Board of Directors

Highly Regarded Veterinary Marketing Executive to Join KindredBio’s Board SAN FRANCISCO, California, (January 22, 2013) – Kindred Biosciences, Inc., (KindredBio) a biotechnology company focused on developing therapies for companion animals, today announced that Mr. Ervin Veszprémi will be joining the company’s Board of Directors.